Merck & Co. - MRK Projected Future Earnings

Corporate emblem and logo of MSD (MRK)

Merck & Co., Inc. (MRK) is a recognized medical leader with an impeccable reputation, built on innovations in cancer therapy. The company generates revenue by supplying unique vaccines and medications to global hospital networks. The share price retrospective on GURU.Markets reflects profit dynamics, which currently stand at 22.01. The primary challenge remains the upcoming loss of exclusive rights to its main blockbuster drug.

Merck & Co., Inc. (MRK): Expected Net Profit from 07/04/2022 to 11/15/2026

Analytical breakdowns for Merck Sharp & Dohme (MRK)

- stock quotes and analyst forecast:
Stock Quotes Merck|MRK - Fair Value Consensus
- issuer market value details:
Market Capitalization Merck Sharp & Dohme|MRK - Value Adjusted for Debt and Cash
- book capitalization indicators:
Net Assets per Single Share Merck|MRK - Total Stockholders' Equity|Market Value to Book Value Ratio merck.com|MRK - Aggregate Company Assets
- company total debt and liquidity indicators:
Total Debt to Capital Merck & Co., Inc.|MRK - Long-Term Debt to Capital Ratio|Short-Term Debt to Capital merck.com|MRK - Company Total Debt Obligations|Debt to Book Capitalization Ratio MSD|MRK - Company Long-Term Indebtedness|Company Short-Term Debts Merck|Quick Liquidity merck.com
- net income and valuation ratios data:
MRK - Net Income|Projected Future Earnings Merck & Co., Inc.|MRK - Market Cap to Earnings|Future Price to Earnings Merck Sharp & Dohme|MRK - Growth-Adjusted Payback Ratio|EV/EBITDA Multiple Merck Sharp & Dohme|MRK - Operating profit before deduction of amortization|Earnings per share for the last twelve months Merck|MRK - Net earnings per share (EPS TTM)|Year-over-year net earnings per share growth for the last 12 months merck.com|MRK - Earnings per share increase in current year|Projected earnings per share growth rate for next year Merck & Co., Inc.
- total revenue and sales volume data:
MRK - Company Total Sales|Company Future Sales Volume Merck|MRK - Market Capitalization-to-Revenue Ratio|Forward P/S Multiple Merck Sharp & Dohme
Initial company analysis:MRK, Merck Sharp & Dohme
Finished products of Merck & Co.

Merck & Co., Inc. (MRK) transition toward climate neutrality and "green chemistry" is impacting its cost structure, which is reflected in the dynamics of the business's expected net profit. This indicator aggregates discounted future cash flows while accounting for current risks, allowing investors to assess the asset's fundamental stability and avoid a value trap during capital allocation.

Competing companies

Future Profit LLY|Projected Future Earnings Abbvie|Projected Future Earnings AZN|NVS (Novartis Pharma) - Expected Net Income|Expected Profit Novo Nordisk AS NVO|Expected Net Income AMGN|PFE - Expected Profit|SNY: Expected Profit|BMY: Projected Future Earnings|Net Profit Forecast GSK|TAK (takeda.com) - Projected Future Earnings|Net Profit Forecast TEVA (Teva)|Expected Profit Dr. Reddy's Lab (RDY)|Company Profit Forecast Viatris Inc|Expected Profit Roivant Sciences Ltd. ROIV|ZLAB: Net Profit Forecast|Bausch Health Companies - Projected Future Earnings|Projected Net Profit Cosmos Health Inc. (COSM)